ADAPTIVE BIOTECHNOLOGIES CORPORATION
ADPT US00650F1093
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -50% | -74% | -37% | 26% | 16% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Piskel Kyle CFO |
8.89 USD |
1,929 Sold |
17,149 USD |
16/05/2025 | 16/05/2025 |
| Piskel Kyle CFO |
8.89 USD |
1,929 Sold |
17,149 USD |
15/05/2025 | 16/05/2025 |
| Robins Harlan S CSO |
7.35 USD |
68,412 Sold |
502,828 USD |
01/05/2025 | 01/05/2025 |
| Robins Harlan S CSO |
7.35 USD |
68,412 Sold |
502,828 USD |
01/05/2025 | 01/05/2025 |
| Robins Harlan S CSO |
9.00 USD |
1,698 Sold |
15,282 USD |
24/03/2025 | 24/03/2025 |
| Griffin Michelle Renee |
7.19 USD |
36,291 Sold |
260,932 USD |
13/03/2025 | 13/03/2025 |
| Hershberg Robert |
7.59 USD |
53,000 Sold |
402,270 USD |
12/03/2025 | 12/03/2025 |
| Neupert Peter M |
7.05 USD |
10,000 Sold |
70,500 USD |
10/03/2025 | 10/03/2025 |
| Robins Chad M CEO |
7.64 USD |
102,218 Sold |
780,946 USD |
04/03/2025 | 06/03/2025 |
| Griffin Michelle Renee |
7.94 USD |
15,664 Sold |
124,372 USD |
04/03/2025 | 06/03/2025 |